Studies immune response to a low-dose mpox vaccine in people with and without HIV
Compares immune response and safety of a low-dose mpox vaccine in people with HIV.
Plain-language title generated from the registry record
Registry title: New York City Observational Study of Mpox Immunity
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05654883, who can take part
Where in United States
- NYU Langone HealthNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT05654883
- Record updated
- 27 August 2026
- Original description
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.Read full original descriptionShow less
New York City Observational Study of Mpox Immunity: NYC OSMI
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.
Inclusion: Must be able to understand and sign the Informed Consent Form (ICF); ≥18 years of age; Including breastfeeding and pregnant people; Must have one or the other of criteria a and b, or can have both:; Planning receipt of (in the next 30 days) or have received the mpox vaccine, and/or; people with recent mpox infection who are out of isolation (≥30 days after symptom onset); Willingness and ability to participate in all study procedures.
Exclusion: Contraindication to phlebotomy based on investigator judgement; e.g., anti-coagulation therapy with history of phlebotomy complications, or clinically significant thrombocytopenia; Any condition that, in the opinion of the Investigator, would make study participation unsafe for the individual or would interfere with the objectives of the study; Known clinically significant anemia (i.e., Hb < 10 g/dL).